文献速递神经免疫神经肌肉病

MGTX试验:胸腺切除与泼尼松减停后持续微小表现状态

Minimal manifestation status and prednisone withdrawal in the MGTX trial.
PubMed 文献 · Neurology · 2020-07-01

该研究为MGTX随机试验的事后分析,纳入18-65岁、病程<5年、AChR抗体阳性无胸腺瘤的全身型MG患者,比较胸腺切除+泼尼松与单用泼尼松。5年期间,联合组更常达到持续MMS并完全停用泼尼松(64% vs 38%),中位时间30个月 vs 未达到(p<0.001)。

要点

  • 胸腺切除+泼尼松组64%达到持续MMS并完全停用泼尼松,单用泼尼松组为38%。
  • 联合组达到持续MMS并完全停用泼尼松的中位时间为30个月,单用组未达到中位时间。
  • 单用泼尼松组泼尼松相关不良反应更频繁,且痛苦程度随剂量增加。

核心结论

  • 胸腺切除可提高AChR抗体阳性全身型MG患者达到持续微小表现状态并完全停用泼尼松的可能性。

研究设计与样本

  • MGTX为多中心、随机、评估者盲法3年试验,并设自愿2年延伸期,纳入AChR抗体阳性无胸腺瘤的MG患者。
  • 患者按1:1随机接受胸腺切除+泼尼松或单用泼尼松,入组年龄18-65岁、病程<5年。
  • 所有患者口服泼尼松隔日滴定至100 mg直至达到MMS,随后在维持MMS期间按标准化方案减量。

主要发现

  • 5年研究期间,胸腺切除+泼尼松组达到持续MMS并完全停用泼尼松的比例为64%,单用泼尼松组为38%。
  • 联合组达到持续MMS并完全停用泼尼松的中位时间为30个月,单用组未达到中位时间(p < 0.001)。
  • 泼尼松相关不良症状在单用泼尼松组更频繁,且痛苦程度随泼尼松剂量增加而升高。

关键数值与推荐

  • 持续MMS定义为6个月无MG症状。
  • 达到持续MMS并完全停用泼尼松的比例:胸腺切除+泼尼松组64% vs 单用泼尼松组38%。
  • 达到持续MMS并完全停用泼尼松的中位时间:联合组30个月 vs 单用组未达到(p < 0.001)。

临床怎么用

  • 对于AChR抗体阳性无胸腺瘤的全身型MG患者,胸腺切除联合泼尼松可能更有利于实现持续MMS并完全停用泼尼松。
  • 治疗中需关注泼尼松相关不良反应,单用泼尼松者不良反应更频繁且痛苦程度随剂量增加。

局限性

  • 本研究为MGTX试验的事后分析。
  • 延伸期为自愿参与,可能引入选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To examine whether sustained minimal manifestation status (MMS) with complete withdrawal of prednisone is better achieved in thymectomized patients with myasthenia gravis (MG). METHODS: This study is a post hoc analysis of data from a randomized trial of thymectomy in MG (Thymectomy Trial in Non-Thymomatous Myasthenia Gravis Patients Receiving Prednisone Therapy [MGTX]). MGTX was a multicenter, randomized, rater-blinded 3-year trial that was followed by a voluntary 2-year extension for patients with acetylcholine receptor (AChR) antibody-positive MG without thymoma. Patients were randomized 1:1 to thymectomy plus prednisone vs prednisone alone. Participants were age 18-65 years at enrollment with disease duration less than 5 years. All patients received oral prednisone titrated up to 100 mg on alternate days until they achieved MMS, which prompted a standardized prednisone taper as long as MMS was maintained. The achievement rate of sustained MMS (no symptoms of MG for 6 months) with complete withdrawal of prednisone was compared between the thymectomy plus prednisone and prednisone alone groups. RESULTS: Patients with MG in the thymectomy plus prednisone group achieved sustained MMS with complete withdrawal of prednisone more frequently (64% vs 38%) and quickly compared to the prednisone alone group (median time 30 months vs no median time achieved, p < 0.001) over the 5-year study period. Prednisone-associated adverse symptoms were more frequent in the prednisone alone group and distress level increased with higher doses of prednisone. CONCLUSIONS: Thymectomy benefits patients with MG by increasing the likelihood of achieving sustained MMS with complete withdrawal of prednisone. CLINICALTRIALSGOV IDENTIFIER: NCT00294658. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that for patients with generalized MG with AChR antibody, those receiving thymectomy plus prednisone are more likely to attain sustained MMS and complete prednisone withdrawal than those on prednisone alone.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Lee I, Kuo HC, Aban IB, et al. Minimal manifestation status and prednisone withdrawal in the MGTX trial. Neurology. 2020. PMID: 32611638. doi:10.1212/WNL.0000000000010031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。